← TrialMatch
HomeTrials

Fructose and Liver Diseases in Youth: Help Them FLY

Obesity has been increasing all over the world. This has lead to a significant increase of a liver disease in children called non-alcoholic fatty liver disease (NAFLD). NAFLD is a liver disease that ranges from excess fat being stored in the liver to an inflamed and fatty liver with fibrosis to cirrhosis. NAFLD is thou

Condition(s)Non-alcoholic Fatty Liver Disease
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryObesity has been increasing all over the world. This has lead to a significant increase of a liver disease in children called non-alcoholic fatty liver disease (NAFLD). NAFLD is a liver disease that ranges from excess fat being stored in the liver to an inflamed and fatty liver with fibrosis to cirrhosis. NAFLD is thought to be caused by changes in energy, fat and carbohydrate metabolism induced by diets high in in processed foods. Sugary (especially high fructose corn syrup or HFCS) and fatty foods in processed foods have been shown to produce more insulin resistance, a factor that is thought to cause a fatty liver. Currently the main treatment for NAFLD is weight loss. However, it unknown the best way to achieve this. The investigator has shown previously that adolescents with NAFLD eat
Who can participateInclusion Criteria: * obese boys and girls aged 12-18 years (Tanner Stage: III-V) with clinically diagnosed NAFLD Exclusion Criteria: 1. all patients with a history of a known primary liver disease associated with steatohepatitis (Wilson disease, various metabolic disorders, viral hepatitis) (7); 2. All patients with a known primary diagnosis of Type 2 Diabetes or those on insulin; 3. Patients on medications known to cause hepatic steatosis (e.g., methotrexate, corticosteroids, valproic acid, statins); 4. Patients with evidence of bridging fibrosis (8); and 5. Patients with a known significant history of smoking or alcohol consumption (6, 9) and 6. Any patient undergoing an active weight loss program and/or who has received bariatric surgery for the treatment of obesity 7. Any participant
Ages12 Years to 18 Years
SexAll
Lead sponsorUniversity of Alberta
LocationsEdmonton, Alberta, Canada
Start date2015-04-30
NCT IDNCT05528471
Official listinghttps://clinicaltrials.gov/study/NCT05528471

🔍 Search all trials →